微流体装置作为细胞治疗制造的工艺开发工具。

4区 工程技术 Q2 Biochemistry, Genetics and Molecular Biology
Jorge Aranda Hernandez, Christopher Heuer, Janina Bahnemann, Nicolas Szita
{"title":"微流体装置作为细胞治疗制造的工艺开发工具。","authors":"Jorge Aranda Hernandez,&nbsp;Christopher Heuer,&nbsp;Janina Bahnemann,&nbsp;Nicolas Szita","doi":"10.1007/10_2021_169","DOIUrl":null,"url":null,"abstract":"<p><p>Cellular therapies are creating a paradigm shift in the biomanufacturing industry. Particularly for autologous therapies, small-scale processing methods are better suited than the large-scale approaches that are traditionally employed in the industry. Current small-scale methods for manufacturing personalized cell therapies, however, are labour-intensive and involve a number of 'open events'. To overcome these challenges, new cell manufacturing platforms following a GMP-in-a-box concept have recently come on the market (GMP: Good Manufacturing Practice). These are closed automated systems with built-in pumps for fluid handling and sensors for in-process monitoring. At a much smaller scale, microfluidic devices exhibit many of the same features as current GMP-in-a-box systems. They are closed systems, fluids can be processed and manipulated, and sensors integrated for real-time detection of process variables. Fabricated from polymers, they can be made disposable, i.e. single-use. Furthermore, microfluidics offers exquisite spatiotemporal control over the cellular microenvironment, promising both reproducibility and control of outcomes. In this chapter, we consider the challenges in cell manufacturing, highlight recent advances of microfluidic devices for each of the main process steps, and summarize our findings on the current state of the art. As microfluidic cell culture devices have been reported for both adherent and suspension cell cultures, we report on devices for the key process steps, or unit operations, of both stem cell therapies and cell-based immunotherapies.</p>","PeriodicalId":7198,"journal":{"name":"Advances in biochemical engineering/biotechnology","volume":"179 ","pages":"101-127"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Microfluidic Devices as Process Development Tools for Cellular Therapy Manufacturing.\",\"authors\":\"Jorge Aranda Hernandez,&nbsp;Christopher Heuer,&nbsp;Janina Bahnemann,&nbsp;Nicolas Szita\",\"doi\":\"10.1007/10_2021_169\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cellular therapies are creating a paradigm shift in the biomanufacturing industry. Particularly for autologous therapies, small-scale processing methods are better suited than the large-scale approaches that are traditionally employed in the industry. Current small-scale methods for manufacturing personalized cell therapies, however, are labour-intensive and involve a number of 'open events'. To overcome these challenges, new cell manufacturing platforms following a GMP-in-a-box concept have recently come on the market (GMP: Good Manufacturing Practice). These are closed automated systems with built-in pumps for fluid handling and sensors for in-process monitoring. At a much smaller scale, microfluidic devices exhibit many of the same features as current GMP-in-a-box systems. They are closed systems, fluids can be processed and manipulated, and sensors integrated for real-time detection of process variables. Fabricated from polymers, they can be made disposable, i.e. single-use. Furthermore, microfluidics offers exquisite spatiotemporal control over the cellular microenvironment, promising both reproducibility and control of outcomes. In this chapter, we consider the challenges in cell manufacturing, highlight recent advances of microfluidic devices for each of the main process steps, and summarize our findings on the current state of the art. As microfluidic cell culture devices have been reported for both adherent and suspension cell cultures, we report on devices for the key process steps, or unit operations, of both stem cell therapies and cell-based immunotherapies.</p>\",\"PeriodicalId\":7198,\"journal\":{\"name\":\"Advances in biochemical engineering/biotechnology\",\"volume\":\"179 \",\"pages\":\"101-127\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in biochemical engineering/biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1007/10_2021_169\",\"RegionNum\":4,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in biochemical engineering/biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/10_2021_169","RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 1

摘要

细胞疗法正在生物制造行业创造一种范式转变。特别是对于自体治疗,小规模的处理方法比传统上在行业中使用的大规模方法更适合。然而,目前制造个性化细胞疗法的小规模方法是劳动密集型的,并且涉及许多“开放事件”。为了克服这些挑战,遵循盒装GMP概念的新型细胞制造平台最近上市(GMP:良好生产规范)。这些是封闭的自动化系统,内置泵用于流体处理和传感器用于过程监控。在一个小得多的规模,微流体装置表现出许多相同的特点,目前的GMP-in-a-box系统。它们是封闭的系统,流体可以处理和操纵,并且集成了传感器以实时检测过程变量。它们由聚合物制成,可以一次性使用,即一次性使用。此外,微流体提供了对细胞微环境的精细时空控制,保证了结果的可重复性和可控制性。在本章中,我们考虑了细胞制造中的挑战,重点介绍了每个主要工艺步骤的微流体装置的最新进展,并总结了我们对当前技术状况的发现。由于微流体细胞培养装置已被报道用于贴壁和悬浮细胞培养,我们报告了用于干细胞治疗和细胞免疫治疗的关键工艺步骤或单元操作的设备。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Microfluidic Devices as Process Development Tools for Cellular Therapy Manufacturing.

Cellular therapies are creating a paradigm shift in the biomanufacturing industry. Particularly for autologous therapies, small-scale processing methods are better suited than the large-scale approaches that are traditionally employed in the industry. Current small-scale methods for manufacturing personalized cell therapies, however, are labour-intensive and involve a number of 'open events'. To overcome these challenges, new cell manufacturing platforms following a GMP-in-a-box concept have recently come on the market (GMP: Good Manufacturing Practice). These are closed automated systems with built-in pumps for fluid handling and sensors for in-process monitoring. At a much smaller scale, microfluidic devices exhibit many of the same features as current GMP-in-a-box systems. They are closed systems, fluids can be processed and manipulated, and sensors integrated for real-time detection of process variables. Fabricated from polymers, they can be made disposable, i.e. single-use. Furthermore, microfluidics offers exquisite spatiotemporal control over the cellular microenvironment, promising both reproducibility and control of outcomes. In this chapter, we consider the challenges in cell manufacturing, highlight recent advances of microfluidic devices for each of the main process steps, and summarize our findings on the current state of the art. As microfluidic cell culture devices have been reported for both adherent and suspension cell cultures, we report on devices for the key process steps, or unit operations, of both stem cell therapies and cell-based immunotherapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in biochemical engineering/biotechnology
Advances in biochemical engineering/biotechnology 工程技术-生物工程与应用微生物
CiteScore
5.70
自引率
0.00%
发文量
29
期刊介绍: Advances in Biochemical Engineering/Biotechnology reviews actual trends in modern biotechnology. Its aim is to cover all aspects of this interdisciplinary technology where knowledge, methods and expertise are required for chemistry, biochemistry, microbiology, genetics, chemical engineering and computer science. Special volumes are dedicated to selected topics which focus on new biotechnological products and new processes for their synthesis and purification. They give the state-of-the-art of a topic in a comprehensive way thus being a valuable source for the next 3 - 5 years. It also discusses new discoveries and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信